PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of oncotargetLink to Publisher's site
 
Oncotarget. 2017 February 14; 8(7): 11566–11578.
Published online 2016 December 24. doi:  10.18632/oncotarget.14141
PMCID: PMC5355286

Anaplastic lymphoma kinase L1198F and G1201E mutations identified in anaplastic thyroid cancer patients are not ligand-independent

Abstract

Activating mutations in full length anaplastic lymphoma kinase (ALK) have been reported in neuroblastoma and in anaplastic thyroid cancer. ALK-L1198F and ALK-G1201E mutations were originally identified in anaplastic thyroid cancer (ATC) and characterized as constitutively activating mutations. In this study, we employed in vitro cell culture assays together with biochemical and in vivo Drosophila analyses to characterize their sensitivity to either activation by the FAM150A (AUG-β) and FAM150B (AUG-α) ALK ligands or inhibition by ALK inhibitors. Here we report that neither ALK-L1198F nor ALK-G1201E mutations result in ligand independent gain-of-function (GOF) activity in either in vitro biochemical analysis or the various model systems employed. ALK-L1198F is activated by the FAM150 (AUG) ligands and its ligand-dependant activity is similar to the wild type full length ALK receptor. ALK-G1201E is only very weakly activated by the FAM150 (AUG) ligands, most likely due to impaired protein stability. We conclude that neither ALK-L1198F nor ALK-G1201E displays ligand independent kinase activity, with ALK-L1198F belonging to the class of ligand dependent ALK mutations which are not constitutively active but that responds to ligand activation, while the ALK-G1201E mutation generates an unstable receptor with very low levels of kinase activity.

Keywords: brigatinib, ATC, ceritinib, crizotinib, neuroblastom

INTRODUCTION

Anaplastic lymphoma kinase (ALK) belongs to the insulin receptor kinase subfamily of receptor tyrosine kinases [1], and was originally identified as a fusion protein with nucleophosmin (NPM) in anaplastic large cell lymphoma (ALCL) [2, 3]. During the last decade numerous ALK fusion proteins have been described in various cancers, such as inflammatory myofibroblastic tumors (IMT), non-small-cell lung cancer (NSCLC), diffuse large B cell lymphomas (DLBCL), renal cell carcinoma, breast cancer, colon carcinoma, serous ovarian carcinoma and oesophageal squamous cell carcinoma [1]. The full length ALK receptor possesses an extracellular ligand-binding domain, a transmembrane domain and an intracellular tyrosine kinase domain (TKD), and is activated by the FAM150A (AUG-β) and FAM150B (AUG-α) ligands [4, 5].

Point mutations in full length ALK have been observed in both familial and sporadic neuroblastoma, a common childhood cancer which arises in the tissues of the sympathetic nervous system [611]. Recently ALK point mutations were reported in anaplastic thyroid cancer (ATC), at residues ALK-L1198F and ALK-G1201E [12]. Most neuroblastoma mutations are situated within the kinase domain of ALK, mainly located around the α-C-helix and the activation loop. The ALK mutations found in ATC are located in the vicinity of the ATP-binding site of the kinase domain/hinge region between the N- and C-lobes (Figure (Figure1A).1A). ALK-positive neuroblastoma mutants fall into three classes: gain-of-function (GOF) ligand independent mutations, ligand dependent mutations which are not constitutively active and require activation with either FAM150 (AUG) ligands or agonist antibodies, and finally kinase-dead mutations [13]. Whether the ligand dependent or kinase-dead mutations are of importance in initiation and progression of disease is still unclear and will require future investigation, particularly when considering potentially complex mechanistic scenarios as the BRAF paradox [1416]. Since the FAM150 (AUG) ligands are able to drive further activation of ALK mutants from neuroblastoma, dysregulation of the ALK ligands may potentially play a role in neuroblastoma [4].

Figure 1
Characterization of ALK-L1198F and ALK-G1201E mutations with cell culture systems and biochemical assays

The ALK-L1198F and ALK-G1201E mutations identified in ATC were reported to be constitutively active ALK mutations that strongly promote cell focus formation, anchorage-independent growth and cell invasion [12]. Both ALK-L1198F and ALK-G1201E activated downstream signalling, such as the PI3K/Akt and MAP kinase pathways [12]. Recently, an L1198F mutation in ALK was reported in an ALK rearranged NSCLC patient who first developed a crizotinib resistance mutation (ALK-C1156Y) and thereafter developed a second mutation ALK-C1156Y/L1198F, upon treatment with the third generation ALK tyrosine kinase inhibitor (TKI) lorlatinib, which results in a mutated ATP binding site that is once again crizotinib sensitive [24]. Thus further investigation of the ALK-L1198F mutation is of clinical importance not only in ATC in the context of the full length receptor but also in the EML4-ALK fusion protein involved in NSCLC.

Initially our aim was to investigate the sensitivity of ALK-L1198F and ALK-G1201E to different ALK TKIs, providing clinically relevant therapeutic information. To characterize these mutations in detail, we performed several different assays, such as neurite outgrowth and in vitro kinase assays as well as ectopic expression in the Drosophila eye. In our hands the postulated GOF mutation L1198F displays activity similar to that of wild type ALK, while the G1201E mutation results in an unstable receptor that behaves more like a kinase-dead ALK receptor.

RESULTS

Initial investigation of the ALK-L1198F and ALK-G1201E mutant receptors

A sensitive functional readout for receptor tyrosine kinase activity in PC12 cells is the ability of cells to induce neurite outgrowth [13]. We and others have previously shown that activation of ALK triggers differentiation of PC12 cells into sympathetic-like neurons, a process that is characterized by extension of neurites [11, 13, 17]. ALK-L1198F and ALK-G1201E have been reported as mutations with constitutive ALK tyrosine kinase activity in ATC [12]. Both residues are located in the hinge region that connects the N-terminal and C-terminal lobes of ALK kinase domain and contributes to the formation of ATP-binding site together with the glycine-rich P-loop at the interlobe cleft [18, 19] (Figure (Figure1A).1A). Our initial aim was to investigate whether the constitutive ALK kinase activity reported for ALK-L1198F and ALK-G1201E could be abrogated with either first or second generation ALK TKIs. However, these experiments could not be performed since neither ALK-L1198F nor ALK-G1201E were able to generate neurite outgrowth when expressed in PC12 cells (Figure (Figure1B).1B). This is in contrast to the ALK-F1174L positive control, which is a well characterised GOF ALK neuroblastoma mutation [7, 8], that induced robust neurite outgrowth (Figure (Figure1B).1B). Stimulation of ALK-L1198F and ALK-G1201E with an agonist antibody (mAb46) [20] led to neurite outgrowth, however, less neurite outgrowth was observed when compared to wild type ALK and the ALK-F1174L positive control (Figure (Figure1B).1B). Consistent with the neurite outgrowth results, stimulation of ALK-WT and ALK-L1198F led to ALK phosphorylation and activation of downstream MAPK/ERK signaling (Figure (Figure1C).1C). While ALK-L1198F displayed reduced levels of both ALK and ERK1/2 activation upon stimulation when compared to ALK-WT, stimulation of ALK-G1201E did not result in any detectable activity (Figure (Figure1C).1C). Moreover, both ALK-L1198F and ALK-G1201E failed to generate focus formation in a NIH 3T3 transformation assay (Figure (Figure1E).1E). In contrast, ALK-F1174L displayed robust focus formation (Figure (Figure1E).1E). The presence of ALK proteins in NIH3T3 cells during the focus formation assay was confirmed by western blot (Figure (Figure1F).1F). These results indicate that neither ALK-L1198F nor ALK-G1201E is ligand-independent GOF mutant in our hands. In vitro kinase assays were performed as a complement to these analyses. ALK-F1174L displayed the highest tyrosine kinase activity - almost 4 times that of wild type ALK (Figure (Figure1D).1D). In contrast, ALK-L1198F kinase activity was 50% of wild type ALK, while ALK-G1201E did not show any notable kinase activity (Figure (Figure1D).1D). The kinase assay results obtained are consistent with observations in PC12 and NIH 3T3 cells (Figure (Figure1B1B and and1C).1C). Taken together, our data strongly suggests that both ALK-L1198F and ALK-G1201E lead to impaired ALK activity and are not ligand-independent GOF mutations.

FAM150A (AUG-β) and FAM150B (AUG-α) activate the ALK-L1198F and ALK-G1201E mutants

We next examined whether ALK-L1198F and ALK-G1201E were activated/phosphorylated upon stimulation with the FAM150A (AUG-β) and FAM150B (AUG-α) ligands. In the absence of stimulation neither ALK-L1198F nor ALK-G1201E gave rise to neurite outgrowth upon expression in PC12 cells (Figures (Figures2A2A and and2C).2C). However, upon stimulation with FAM150A (AUG-β) or FAM150B (AUG-α) ligands both ALK-L1198F and ALK-G1201E were able to mediate neurite outgrowth, although at levels less than those observed with wild type ALK or the constitutively active ALK-F1174L neuroblastoma mutant (Figure (Figure2A2A and and2C).2C). While both the ALK-F1174L positive control and wild type ALK were phosphorylated upon stimulation with either FAM150A (AUG-β) or FAM150B (AUG-α) (Figure (Figure2B2B and and2D),2D), stimulation of ALK-L1198F led to reduced levels of ALK Y1604 phosphorylation when compared with wild type ALK, while ALK-G1201E Y1604 phosphorylation was barely detectable (Figure (Figure2B2B and and2D).2D). In agreement with the levels of ALK Y1604 phosphorylation of the ALK-G1201E mutant, we were unable to detect activation of downstream ALK targets such as ERK1/2 with FAM150A (Figure (Figure2B),2B), although low levels of ERK activation were seen in response to FAM150B (Figure (Figure2D).2D). We also observed that the ALK-G1201E mutant was expressed at reduced levels when compared with either wild type ALK or the ALK-F1174L and ALK-L1198F mutants. In contrast, the ALK-F1174L positive control activates MAPK/ERK signalling even in the absence of ligand (Figure (Figure2B2B and and2D).2D). Upon stimulation with the either FAM150A (AUG-β) or FAM150B (AUG-α) wild type ALK mediated ERK1/2 phosphorylation. The remaining ALK ATC mutation - ALK-L1198F - did result in activation of ERK1/2 upon stimulation with FAM150A (AUG-β) or FAM150B (AUG-α), although stimulation was not as robust as that observed with either wild type ALK or the ALK-F1174L mutant (Figure (Figure2B2B and and2D2D).

Figure 2
Activation of ALK-L1198F and ALK-G1201E by ALK ligands FAM150A (AUG-β) and FAM150B (AUG-α)

Given our consistent observation of low levels of expression of the ALK-G1201E mutant we decided to investigate this further. Firstly, both ALK-L1198F and ALK-G1201E expression constructs were confirmed by sequencing to exclude any possibilities that an error had occurred during construction. We next mutated the ALK-G1201E mutant back to wild type. This new revertant wild type ALK was once again stably expressed when compared with the ALK-G1201E mutant (Figure (Figure1C).1C). Moreover, upon stimulation with mAb46 the wild type that had been reverted from ALK-G1201E re-acquired the ability to become phosphorylated and to activate downstream ERK1/2 again (Figure (Figure1C)1C) and therefore to give neurite outgrowth (Figure (Figure1B).1B). These data suggest that the ALK-G1201E mutation generates an unstable protein that displays very low levels of kinase activity. Based on these results we hypothesized that substitution of G1201 to an amino acid with a bulkier side chain may destabilize the protein thereby resulting in reduced kinase activity, reflecting a structural constraint at residue 1201 for amino acids with smaller side chain. To test this hypothesis, we generated ALK-G1201R and ALK-G1201A mutations (Supplementary Figure 1). In keeping with our hypothesis, the ALK-G1201R mutation was poorly expressed and exhibited impaired kinase activity when compared with wild type ALK. In contrast, the ALK-G1201A mutation was well expressed and responded to stimulation with the agonist antibody mAb46 in a manner similar to wild type ALK (Supplementary Figure 1).

Taken together, our results indicate that neither of the ATC ALK-L1198F/ALK-G1201E mutations is as active as wild type ALK when stimulated with either FAM150A (AUG-β) or FAM150B (AUG-α). Further, the ALK-G1201E protein appears to be intrinsically unstable. Thus, we are unable to produce evidence that either ALK-L1198F or ALK-G1201E is a GOF mutation in ALK.

Examination of ALK-L1198F and ALK-G1201E activity in the Drosophila eye

Finally we employed ectopic expression of ALK-L1198F and ALK-G1201E in the Drosophila model to challenge the ATC mutations. Drosophila melanogaster has been successfully employed as an in vivo model to characterize human ALK mutations, since this system provides a very clean background [11, 13]. The Drosophila Alk ligand, Jelly Belly (Jeb), is unable to activate either human or mouse ALK orthologues [11, 13, 21, 22], however, co-expression with the human ALK ligands FAM150A (AUG-β) or FAM150B (AUG-α) provides robust activation of the human receptor in the Drosophila eye [4] (Figure (Figure3I3I and and3J).3J). To further characterize the activating potential of the human ALK-L1198F and ALK-G1201E mutations, we generated transgenic fly lines and employed the GMR-Gal4 driver to direct ectopic protein expression in developing photoreceptors (Figure (Figure3L3L and and3P).3P). As further controls we employed transgenic flies expressing either constitutively active ALK-F1174L (Figure (Figure3D),3D), ligand-dependent wild type ALK (Figure (Figure3H)3H) or ‘kinase dead’ ALK-I1250T [23] (Figure (Figure3T).3T). As observed previously, expression of the well-characterized, ligand-independent ALK-F1174L allele, which encodes for a constitutively active receptor [11], resulted in a severe rough eye phenotype (Figure (Figure3D).3D). A similar phenotype is also found in flies ectopically expressing other ALK GOF alleles [13, 17], whereas expression of human FAM150A (AUG-β), FAM150B (AUG-α), ALK-WT, ALK-L1198F or ALK-G1201E alone (Figure 3E, 3F, 3H, 3L and and3P)3P) did not reveal any obvious phenotype in adult flies when compared to the w1118 and GMR driver controls (Figures (Figures3A3A and and3B).3B). The lack of activity of either human ALK-L1198F or ALK-G1201E mutation in the fly eyes strongly supports the conclusion that they are not GOF in nature but in fact represent ligand-dependent or even loss-of-function (LOF) alleles.

Figure 3
Effects of the ectopic expression of human ALK variants in the Drosophila eye

To address this we co-expressed the previously reported activating ALK ligands FAM150A (AUG-β) or FAM150B (AUG-α) together with either ALK-L1198F or ALK-G1201E in the developing eye. In case of ALK-L1198F we observed a severe rough eye phenotype upon activation with FAM150B (AUG-α) (Figure (Figure3N).3N). Activation with FAM150A (AUG-β) not only led to a rough eye phenotype but also induced pupal lethality (Figure (Figure3M).3M). These effects were indistinguishable from those observed in flies expressing FAM150 (AUG) ligands together with ALK-WT (Figures (Figures3I3I and and3J)3J) suggesting that ALK-L1198F encodes a ligand-dependent, inducible form of the receptor. Surprisingly, co-expression of FAM150B (AUG-α) and ALK-G1201E (Figure (Figure3R)3R) resulted in no obvious defects, resembling the previously characterised non-inducible, ‘kinase-dead’ mutation ALK-I1250T (Figures (Figures3U3U and and3V).3V). Moreover, combined expression of FAM150A (AUG-β) and ALK-G1201E (Figure (Figure3Q)3Q) no longer resulted in lethality but induced a rough eye phenotype suggesting that the ALK-G1201E mutation, while not completely kinase dead, is in fact a LOF allele. Complementary immunofluorescence analysis clearly showed that while ALK-L1198F and ALK-I1250T were strongly expressed in the eye discs of Drosophila third instar larvae (Figures (Figures3O3O and and3W),3W), the amount of detectable ALK protein was much lower in ALK-G1201E expressing eye discs (Figure (Figure3S),3S), in keeping with the results in our mammalian cell expression above. Since the functional ALK-F1174L and ALK-WT transgenes also exhibited lower expression levels than ALK-L1198F (compare Figure 3G, 3K to 3O) it is conceivable that ALK-G1201E encodes for a receptor with impaired function. Taken together, our Drosophila analyses also suggest that neither ALK-L1198F nor ALK-G1201E is a ligand independent GOF ALK mutant.

Sensitivity of ALK-L1198F to ALK inhibitors

The ALK-L1198F mutation in the context of the EML4-ALK fusion oncogene was recently reported in a NSCLC patient treated with ALK inhibitors. The ALK-L1198F that arose in this patient in response to treatment with the third generation ALK TKI, lorlatinib, was shown to be sensitive to inhibition by crizotinib [24]. Since ALK-L1198F does not behave as a GOF mutation in the full length ALK receptor in our hands, we therefore examined the ability of different inhibitors to abrogate its activity in PC12 cells in the presence or absence of ligand stimulation. As readout for ALK activity we employed phosphorylation of ALK Y1604, which reflects ALK activation [13]. We clearly observed that full length ALK-L1198F mutation was more resistant than wild type ALK to lorlatinib inhibition as measured by Y1604 phosphorylation. The IC50 of lorlatinib for ALK-L1198F was 15.4 ± 2.9 nM, approximately 20 times of that for wild type ALK [25]; however the L1198F mutation did not affect the ability of crizotinib to abrogate ALK activity in this assay (Figures (Figures4A4A and and4B).4B). The ALK-L1198F mutation caused a mild resistance to another next-generation ALK TKI brigatinib (Figures (Figures4A4A and and4B).4B). The FDA-approved second-generation ALK TKI ceritinib was completely unable to inhibit the activity of ALK-L1198F in response to FAM150 (AUG) ligand activation, since no inhibition of ALK Y1604 phosphorylation was observed even with 500 nM of ceritinib. The observed IC50 values of ALK-L1198F for brigantinib, crizotinib and lorlatinib were in a similar range (10.3 nM to 15.4 nM) (Figures (Figures4A4A and and4B).4B). Taken together, our results and those recently reported for the EML4-ALK fusion in NSCLC [24] indicate that ceritinib is not an option for treatment of patients harbouring the L1198F mutation in either the full length ALK or the EML4-ALK fusion protein. The L1198F mutation in full length ALK probably mediates a steric clash between the phenylalanine residue and ceritinib in a similar manner seen when modelling lorlatinib in the EML4-ALK C1156Y-L1198F mutant [24] (Figure (Figure5B).5B). As a read out, the ALK-L1198F-ceritinib interaction increases the half maximal inhibitory ceritinib concentration from 5.3 nM to more than 500 nM (Figure (Figure4B).4B). Modelling of brigatinib (Figures (Figures5C5C and and5D),5D), lorlatinib [24] and crizotinib [24] to ALK does not reveal any obvious steric hindrance. However, investigation of the EML4-ALK-L1198F mutation has been reported to show a more favourable binding to crizotinib relative to wild type EML4-ALK [24]

Figure 4
Inhibition profiling of ALK TKIs on ALK-L1198F
Figure 5
Structural modelling of ceritinib and brigatinib binding to ALK-WT and ALK-L1198F

DISCUSSION

Taken together, the results presented here clearly show that ALK-L1198F and ALK-G1201E are not GOF mutations in the context of full length ALK. Furthermore, mutation of G1201E results in an unstable protein with dramatically reduced kinase activity. The observed problems with protein stability of the ALK-G1201E mutant presents a challenge in addressing whether its low level of activity is a result of reduced kinase activity or protein levels or a combination of both. Clearly reversion of ALK-G1201E to ALK-E1201G results in a protein that is expressed and can be stimulated with ligands, such as agonist antibody or ligands FAM150A and B. Further, the hypothesis that substitution of G1201 to an amino acid with a bulkier side chain, such as glutamate or arginine may destabilize the protein drastically impacting on kinase activity is supported by our data. Thus, our analyses suggest structural constraints at residue 1201 in ALK. Replacing the G1201 with another bulky residue, arginine in this case, also results in an unstable protein. In contrast, replacing G1201 with alanine results in a change of stability or kinase activity to levels comparable with wild type ALK.

Based on our findings, the involvement of ALK activating mutations in the context of the full length ALK receptor in thyroid cancer should be carefully re-evaluated. In contrast to the single report of activating ALK mutations (ALK-L1198F and ALK-G1201E) in the full length receptor [12], a number of articles have reported ALK fusion genes in thyroid cancer, where they appear to represent a small fraction of papillary thyroid carcinoma (PTC). Fusion partners involved include EML4, STRN, TFG, and GTF2IRD1 [2632]. ALK fusions have also been descried in medullary thyroid cancer (EML4-ALK and Glutamine:fructose-6-phosphate transaminase 1 (GFPT1)-ALK), with patient response to crizotinib reported in an EML4-ALK patient [33].

Both clinical and preclinical data support ALK fusion proteins are drivers in tumorigenesis [34], where oligomerisation mediated by the ALK fusion partner serves to dimerize and activate the ALK kinase domain. The appearance of clinical TKI-resistant ALK mutations, which are mostly clustered around the ATP/TKI binding site in the kinase domain result in unfavourable binding for the specific ALK TKIs employed. The ALK-L1198F mutation in the context of the EML4-ALK fusion protein leads to a dramatically reduced ability of this mutant to be inhibited by ceritinib as compared to wild type EML4-ALK [24]. However, the oncogenic activity of the EML4-ALK-L1198F mutant is still due to oligomerisation and activation driven by the EML4 fusion partner. In contrast, mutation of L1198F in the context of the full length receptor does not result in ligand independent ALK activation.

The COSMIC database reports ALK sequencing results for 720 thyroid cancer samples, identifying 12 samples with mutations, including ALK-L1198F and ALK-G1201E. While it is possible that some of the other candidate mutations may be activating in nature they have not been tested and none overlap with mutations shown to activate ALK in neuroblastoma [35]. Whether cellular context, in a thyroid cell environment, plays a role in the in vivo activity of these ALK mutations remains to be determined. In conclusion, while mutations in full length ALK leading to activation of the receptor are well characterised in neuroblastoma and supported by a substantial body of work, the activation of full length ALK in thyroid cancer requires further critical evaluation. Finally, ceritinib may not be an option for treatment of patients harboring the L1198F mutations in either the full-length ALK or the EML4-ALK fusion protein.

MATERIALS AND METHODS

Generation of human ALK mutant constructs

ALK-L1198F, ALK-G1201E and other ALK-G1201 mutation constructs were generated based from pcDNA3-ALK-WT (NM_004304.3) by Eurofins Genomics. ALK-F1174L has been described previously [11]. ALK-G1201E→WT was generated with QuickChange Site-Directed Mutagenesis Kit (Stratagene) in which the G1201E mutation was mutated back to wild type. All the mutations generated in the kinase domain were confirmed by sequencing from both directions.

Neurite outgrowth assay

PC12 cells (2×106) were transfected by electroporation in an Amaxa electroporator, using 0.75 μg of ALK constructs and 0.5 μg of pEGFP-C1 (Clontech) and 100 μL of Ingenio electroporation solution (Mirrus Bio LCC). After transfection, cells were transferred to DMEM supplemented with 7% horse serum and 3% FBS and seeded into 24-well plates. An agonist monoclonal antibody mAb46 was added at 1 μg/mL to activate the ectopically expressed ALK receptors. Two days after transfection, the percentage of GFP-positive and neurite-carrying cells versus GFP-positive cells was estimated under a Zeiss Axiovert 40 CFL microscope. To be judged as a neurite-carrying cell, the neurites of the cell had to reach at least twice the length of the cell body. Experiments were performed in triplicates and each sample within an experiment was assayed in duplicate.

Cell culture, lysis, and immunoblotting

PC12 cells were transfected with different ALK constructs by electroporation. Cells were serum-starved for 36 hours prior to stimulation with 1 μg/ml of the activating mAb46 for 30 minutes Cells were washed with ice-cold PBS prior to harvest in lysis buffer [25 mM of Tris-Cl, pH7.5, 150 mM of NaCl, 1% (v/v) Triton X-100, 1 mM of DTT, protease inhibitor cocktail tablet (Roche)]. Cell lysates were cleared by centrifugation at 14,000 rpm for 15 minutes at 4°C. Samples were boiled in 1x SDS sample buffer and analyzed by immunoblotting. Primary antibodies used for immunoblotting were: anti-pan-ERK (1:10,000) from BD Transduction Laboratories (Franklin Lakes, NJ); anti-pALK (Y1604) and anti-pERK1/2 (T202/Y204) from Cell Signaling Technology (Danvers, MA); anti-FAM150A and anti-FAM150B antibodies from Atlas Antibodies (Stockholm). Monoclonal antibody 135 (anti-ALK) was produced in the Hallberg laboratory against the extracellular domain of ALK as described [20]. Horseradish-peroxidase-conjugated secondary antibodies goat anti-rabbit IgG and goat anti-mouse IgG (1:5,000) were from Thermo Scientific (Waltham, MA).

Stimulation with ALK ligands FAM150A (AUG-β) and FAM150B (AUG-α)

For neurite outgrowth assays, PC12 cells (2×106) were transfected by electroporation in an Amaxa electroporator, using 0.3 μg of pcDNA3 vector or different ALK constructs, together with 0.5 μg of pEGFP-C1, and with or without 1 μg of either FAM150A (AUG-β) or FAM150B (AUG-α) plasmid and 100 μL of Ingenio electroporation solution (Mirrus Bio LCC). After transfection, cells were transferred to DMEM supplemented with 7% horse serum and 3% FBS and seeded into 24-well plates. After twenty four hours, cells were analysed as described above. PC12 cells transfected with ALK-F1174L alone were used as control.

For immunoblotting, PC12 cells (2×106) were electroporated with 0.3 μg of pcDNA3 or different ALK constructs, together with or without 1 μg of either FAM150A (AUG-β) and FAM150B (AUG-α) plasmid. PC12 cells electroporated with ALK-F1174L alone were used as positive control. Twenty-four hours after transfection, cells were starved for another 30-36 hours prior to lysis. Cells were then lysed and analysed with immunoblotting as described above.

Generation of recombinant ALK TKD proteins

DNA encoding ALK residues 1090-1416 which includes the whole tyrosine kinase domain (TKD) was amplified from different ALK constructs with Phusion High-Fidelity DNA polymerase (ThermoScientific) and cloned into pFastBac/NT-TOPO vector (Invitrogen) for expression of 6× histidine-tagged recombinant ALK TKD proteins in Sf21 cells. Recombinant baculovirus was generated using the Bac-to-Bac baculovirus expression system (Invitrogen). Sf21 cells were infected with P2 virus stock for 3 days at 27°C and then lysed in native Ni-NTA lysis buffer (50 mM NaH2PO4 pH8.0, 300 mM NaCl, 10 mM imidazole, 1% Triton X-100 and protease inhibitor cocktail). After centrifugation, His-tagged TKD proteins were recovered from the lysis supernatant using Ni-NTA His·Bind resins (Novagen). After two washes, the TKD proteins bound to resins were incubated in 50 mM Tris-Cl pH 7.4, 150 mM NaCl, 10 mM MgCl2 and 2 mM ATP at 30°C for 1 hour for further ALK TKD autophosphorylation. After two additional washes, ALK TKD proteins were eluted and their concentrations were determined by absorbance at 280 nm. Purity of ALK TKD proteins was assessed by SDS-PAGE and Coomassie blue staining.

In vitro kinase assays

Analysis of substrate phosphorylation by ALK TKD employed a peptide mimic of the ALK activation loop with sequence: ARDIYRASYYRKGGCAMLPVK (Caslo, Danmark), referred to as YYY peptide [36]. Assays were performed using radiolabeled ATP as described previously [37]. Different amount of ALK TKD proteins were used with fixed concentration of ATP and peptide at 0.1 mM and 0.2 mM respectively. Assays were conducted at 30°C for 30 minutes and the incorporation of 32P from γ-32P ATP into the substrate was detected with Wallac 1410 Liquid Scintillation Counter (GMI). Assays were performed three times independently and each sample within an assay was set in duplicate.

Transformation assay

NIH 3T3 cells (4.5×104) were seeded in collagen-coated 12-well plates prior to transfection for 6 hours with 1.75 μg of pcDNA3 vector, pcDNA3-ALK-WT, pcDNA3-ALK-L1198F, pcDNA3-ALK-G1201E or pcDNA3-ALK-F1174L together with 5 μl of Lipofectamine 2000 (Invitrogen) in 0.3 ml Opti-MEM. The next day, 60% of the cells were transferred to six-well plates and maintained in DMEM with 10% heat-inactivated FBS and 0.5 mg/ml G418 until the cells reached confluency. Then, the cells were cultivated in DMEM with 5% heat-inactivated FBS and 0.25 mg/ml G418 for approximately 10 days. The cells were then fixed using methanol and stained with 0.25% crystal violet. The focus intensities were subsequently analysed [17].

Expression of human ALK constructs in the Drosophila eye

Standard Drosophila husbandry procedures were followed. Stocks were maintained on a potato-mash based diet at room temperature. Crosses were performed at 25°C and 60% humidity level. The UAS-ALK-L1198F and UAS-ALK-G1201E constructs were generated using standard cloning techniques and transgenic flies were obtained by injection (BestGene Inc.). white1118 (w1118) flies were used as control; GMR-Gal4 (#1104) was received from the Bloomington Drosophila Stock Center at Indiana University (BDSC; NIH P40OD018537). UAS-ALK, UAS-ALK-F1174L, UAS-ALK-I1250T as well as UAS-FAM150A (AUG-β) and UAS-FAM150B (AUG-α) were used for ectopic expression studies in the developing Drosophila eye employing the GAL4-UAS system. Staining of imaginal discs was described previously [38]. The rabbit monoclonal ALK (D5F3) antibody was purchased from Cell Signalling and employed at a 1:200 dilution. The hybridoma, monoclonal mouse antibody 4F3 (anti-discs large; employed at 1:500), deposited by Corey Goodman was obtained from the Developmental Studies Hybridoma Bank (DSHB), created by the NICHD of the NIH and maintained at The University of Iowa. Samples were analysed under Zeiss Axio Imager.Z2 and AxioZoom.V16 microscopes. Images were acquired with a Zeiss LSM800 confocal microscope or with an Axiocam 503 colour camera employing ZEN blue edition software.

ALK inhibitor profiles on ALK-L1198F mutation

PC12 cells (2×106) were transfected by electroporation in an Amaxa electroporator using 1.5 μg of ALK L1198F construct and 100 μL of Ingenio electroporation solution (Mirrus Bio LCC). Cells from three electroporations were pooled together, mixed and equally seeded into 9 wells of one 24-well plate. After 24-36 hours culture, cells were treated with serial dilutions of the indicated inhibitors for 1.5 hours before being stimulated with FAM150A (AUG-β) for another 30 minutes. Cells were washed with cold 1X PBS and lysed with 1X SDS sample buffer and samples were boiled at 95°C for 5 minutes. Phospho-ALK (Y1604) antibody was used to detect ALK phosphorylation and ALK mAb135 was used to detect total ALK. The intensity of pALK (Y1604) and total ALK bands was quantified with Image Studio Lite 3.1 software. Data were normalised to the 0 nM inhibitor samples. GraphPad Prism 6.0 was used to calculate IC50 values by fitting data to a log (inhibitor concentration) vs. normalised response (variable slope) equation.

SUPPLEMENTARY MATERIALS FIGURES

Footnotes

Contributed by

Author contributions

J.G., G.W., J.S., D.C. and F.H. performed experiments and data analysis. R.P. and B.H. coordinated the study, participated in the design of the experiments and interpretation of the data. All authors were involved in the writing of the manuscript.

CONFLICTS OF INTEREST

The authors declare no competing financial interest.

FUNDING

This work was supported by the Swedish Cancer Society (15/391 to RHP; 15/775to BH), the Swedish Childhood Cancer Foundation (2015-0096 to RHP; 2015-80, and 2014-150 to BH), the Swedish Research Council (2015-04466 to RHP; BH 521-2012-2831), the Göran Gustafsson Foundation (RHP) and a SSF Programme Grant (RB13-0204 to RHP and BH). J.G. was supported by a Postdoctoral Research Fellow Position by the Swedish Childhood Cancer Foundation (TJ2016-0088). G.W. was supported by a postdoctoral fellowship from the Swedish Childhood Cancer Foundation (NC2014-0045).

REFERENCES

1. Hallberg B, Palmer RH. Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology. Nat Rev Cancer. 2013;13:685–700. [PubMed]
2. Morris SW, Kirstein MN, Valentine MB, Dittmer KG, Shapiro DN, Saltman DL, Look AT. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science. 1994;263:1281–1284. [PubMed]
3. Shiota M, Fujimoto J, Semba T, Satoh H, Yamamoto T, Mori S. Hyperphosphorylation of a novel 80 kDa protein-tyrosine kinase similar to Ltk in a human Ki-1 lymphoma cell line, AMS3. Oncogene. 1994;9:1567–1574. [PubMed]
4. Guan J, Umapathy G, Yamazaki Y, Wolfstetter G, Mendoza P, Pfeifer K, Mohammed A, Hugosson F, Zhang H, Hsu AW, Halenbeck R, Hallberg B, Palmer RH. FAM150A and FAM150B are activating ligands for Anaplastic Lymphoma Kinase. Elife. 2015:4. [PMC free article] [PubMed]
5. Reshetnyak AV, Murray PB, Shi X, Mo ES, Mohanty J, Tome F, Bai H, Gunel M, Lax I, Schlessinger J. Augmentor alpha and beta (FAM150) are ligands of the receptor tyrosine kinases ALK and LTK: Hierarchy and specificity of ligand-receptor interactions. Proc Natl Acad Sci U S A. 2015;112:15862–15867. [PubMed]
6. Caren H, Abel F, Kogner P, Martinsson T. High incidence of DNA mutations and gene amplifications of the ALK gene in advanced sporadic neuroblastoma tumours. Biochem J. 2008;416:153–159. [PubMed]
7. Chen Y, Takita J, Choi YL, Kato M, Ohira M, Sanada M, Wang L, Soda M, Kikuchi A, Igarashi T, Nakagawara A, Hayashi Y, Mano H, Ogawa S. Oncogenic mutations of ALK kinase in neuroblastoma. Nature. 2008;455:971–974. [PubMed]
8. George RE, Sanda T, Hanna M, Frohling S, Luther W, J 2nd Zhang, Ahn Y, Zhou W, London WB, McGrady P, Xue L, Zozulya S, Gregor VE, Webb TR, Gray NS, Gilliland DG, et al. Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature. 2008;455:975–978. [PMC free article] [PubMed]
9. Janoueix-Lerosey I, Lequin D, Brugieres L, Ribeiro A, de Pontual L, Combaret V, Raynal V, Puisieux A, Schleiermacher G, Pierron G, Valteau-Couanet D, Frebourg T, Michon J, Lyonnet S, Amiel J, Delattre O. Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. Nature. 2008;455:967–970. [PubMed]
10. Mosse YP, Laudenslager M, Longo L, Cole KA, Wood A, Attiyeh EF, Laquaglia MJ, Sennett R, Lynch JE, Perri P, Laureys G, Speleman F, Kim C, Hou C, Hakonarson H, Torkamani A, et al. Identification of ALK as a major familial neuroblastoma predisposition gene. Nature. 2008;455:930–935. [PMC free article] [PubMed]
11. Martinsson T, Eriksson T, Abrahamsson J, Caren H, Hansson M, Kogner P, Kamaraj S, Schonherr C, Weinmar J, Ruuth K, Palmer RH, Hallberg B. Appearance of the novel activating F1174S ALK mutation in neuroblastoma correlates with aggressive tumor progression and unresponsiveness to therapy. Cancer Res. 2011;71:98–105. [PubMed]
12. Murugan AK, Xing M. Anaplastic thyroid cancers harbor novel oncogenic mutations of the ALK gene. Cancer Res. 2011;71:4403–4411. [PMC free article] [PubMed]
13. Chand D, Yamazaki Y, Ruuth K, Schonherr C, Martinsson T, Kogner P, Attiyeh EF, Maris J, Morozova O, Marra MA, Ohira M, Nakagawara A, Sandstrom PE, Palmer RH, Hallberg B. Cell culture and Drosophila model systems define three classes of anaplastic lymphoma kinase mutations in neuroblastoma. Disease models & mechanisms. 2013;6:373–382. [PMC free article] [PubMed]
14. Hatzivassiliou G, Song K, Yen I, Brandhuber BJ, Anderson DJ, Alvarado R, Ludlam MJ, Stokoe D, Gloor SL, Vigers G, Morales T, Aliagas I, Liu B, Sideris S, Hoeflich KP, Jaiswal BS, et al. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature. 2010;464:431–435. [PubMed]
15. Heidorn SJ, Milagre C, Whittaker S, Nourry A, Niculescu-Duvas I, Dhomen N, Hussain J, Reis-Filho JS, Springer CJ, Pritchard C, Marais R. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell. 2010;140:209–221. [PMC free article] [PubMed]
16. Poulikakos PI, Zhang C, Bollag G, Shokat KM, Rosen N. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature. 2010;464:427–430. [PMC free article] [PubMed]
17. Schonherr C, Ruuth K, Yamazaki Y, Eriksson T, Christensen J, Palmer RH, Hallberg B. Activating ALK mutations found in neuroblastoma are inhibited by Crizotinib and NVP-TAE684. Biochem J. 2011;440:405–413. [PubMed]
18. Bossi RT, Saccardo MB, Ardini E, Menichincheri M, Rusconi L, Magnaghi P, Orsini P, Avanzi N, Borgia AL, Nesi M, Bandiera T, Fogliatto G, Bertrand JA. Crystal structures of anaplastic lymphoma kinase in complex with ATP competitive inhibitors. Biochemistry. 2010;49:6813–6825. [PubMed]
19. Lee CC, Jia Y, Li N, Sun X, Ng K, Ambing E, Gao MY, Hua S, Chen C, Kim S, Michellys PY, Lesley SA, Harris JL, Spraggon G. Crystal structure of the ALK (anaplastic lymphoma kinase) catalytic domain. Biochem J. 2010;430:425–437. [PubMed]
20. Moog-Lutz C, Degoutin J, Gouzi JY, Frobert Y, Brunet-de Carvalho N, Bureau J, Creminon C, Vigny M. Activation and inhibition of anaplastic lymphoma kinase receptor tyrosine kinase by monoclonal antibodies and absence of agonist activity of pleiotrophin. J Biol Chem. 2005;280:26039–26048. [PubMed]
21. Yang HL, Eriksson T, Vernersson E, Vigny M, Hallberg B, Palmer RH. The ligand Jelly Belly (Jeb) activates the Drosophila Alk RTK to drive PC12 cell differentiation, but is unable to activate the mouse ALK RTK. J Exp Zool B Mol Dev Evol. 2007;308:269–282. [PubMed]
22. Englund C, Loren CE, Grabbe C, Varshney GK, Deleuil F, Hallberg B, Palmer RH. Jeb signals through the Alk receptor tyrosine kinase to drive visceral muscle fusion. Nature. 2003;425:512–516. [PubMed]
23. Schonherr C, Ruuth K, Eriksson T, Yamazaki Y, Ottmann C, Combaret V, Vigny M, Kamaraj S, Palmer RH, Hallberg B. The Neuroblastoma ALK(I1250T) Mutation Is a Kinase-Dead RTK In Vitro and In Vivo. Transl Oncol. 2011;4:258–265. [PMC free article] [PubMed]
24. Shaw AT, Friboulet L, Leshchiner I, Gainor JF, Bergqvist S, Brooun A, Burke BJ, Deng YL, Liu W, Dardaei L, Frias RL, Schultz KR, Logan J, James LP, Smeal T, Timofeevski S, et al. Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F. N Engl J Med. 2016;374:54–61. [PMC free article] [PubMed]
25. Guan J, Tucker ER, Wan H, Chand D, Danielson LS, Ruuth K, El Wakil A, Witek B, Jamin Y, Umapathy G, Robinson SP, Johnson TW, Smeal T, Martinsson T, Chesler L, Palmer RH, et al. The ALK inhibitor PF-06463922 is effective as a single agent in neuroblastoma driven by expression of ALK and MYCN. Disease models & mechanisms. 2016;9:941–952. [PMC free article] [PubMed]
26. Kelly LM, Barila G, Liu P, Evdokimova VN, Trivedi S, Panebianco F, Gandhi M, Carty SE, Hodak SP, Luo J, Dacic S, Yu YP, Nikiforova MN, Ferris RL, Altschuler DL, Nikiforov YE. Identification of the transforming STRN-ALK fusion as a potential therapeutic target in the aggressive forms of thyroid cancer. Proc Natl Acad Sci U S A. 2014;111:4233–4238. [PubMed]
27. McFadden DG, Dias-Santagata D, Sadow PM, Lynch KD, Lubitz C, Donovan SE, Zheng Z, AJ Le L Iafrate, Daniels GH. Identification of oncogenic mutations and gene fusions in the follicular variant of papillary thyroid carcinoma. The Journal of clinical endocrinology and metabolism. 2014;99:E2457–2462. [PubMed]
28. Perot G, Soubeyran I, Ribeiro A, Bonhomme B, Savagner F, Boutet-Bouzamondo N, Hostein I, Bonichon F, Godbert Y, Chibon F. Identification of a recurrent STRN/ALK fusion in thyroid carcinomas. PLoS One. 2014;9:e87170. [PMC free article] [PubMed]
29. Demeure MJ, Aziz M, Rosenberg R, Gurley SD, Bussey KJ, Carpten JD. Whole-genome sequencing of an aggressive BRAF wild-type papillary thyroid cancer identified EML4-ALK translocation as a therapeutic target. World J Surg. 2014;38:1296–1305. [PubMed]
30. Cancer Genome Atlas Research N Integrated genomic characterization of papillary thyroid carcinoma. Cell. 2014;159:676–690. [PMC free article] [PubMed]
31. Chou A, Fraser S, Toon CW, Clarkson A, Sioson L, Farzin M, Cussigh C, Aniss A, O'Neill C, Watson N, Clifton-Bligh RJ, Learoyd DL, Robinson BG, Selinger CI, Delbridge LW, Sidhu SB, et al. A detailed clinicopathologic study of ALK-translocated papillary thyroid carcinoma. The American journal of surgical pathology. 2015;39:652–659. [PMC free article] [PubMed]
32. Yoshihara K, Wang Q, Torres-Garcia W, Zheng S, Vegesna R, Kim H, Verhaak RG. The landscape and therapeutic relevance of cancer-associated transcript fusions. Oncogene. 2015;34:4845–4854. [PMC free article] [PubMed]
33. Ji JH, Oh YL, Hong M, Yun JW, Lee HW, Kim D, Ji Y, Kim DH, Park WY, Shin HT, Kim KM, Ahn MJ, Park K, Sun JM. Identification of Driving ALK Fusion Genes and Genomic Landscape of Medullary Thyroid Cancer. PLoS Genet. 2015;11:e1005467. [PMC free article] [PubMed]
34. Gainor JF, Shaw AT. Emerging paradigms in the development of resistance to tyrosine kinase inhibitors in lung cancer. J Clin Oncol. 2013;31:3987–3996. [PMC free article] [PubMed]
35. Forbes SA, Beare D, Gunasekaran P, Leung K, Bindal N, Boutselakis H, Ding M, Bamford S, Cole C, Ward S, Kok CY, Jia M, JW De T Teague, Stratton MR, McDermott U, et al. COSMIC: exploring the world's knowledge of somatic mutations in human cancer. Nucleic Acids Res. 2015;43(Database issue):D805–811. [PMC free article] [PubMed]
36. Donella-Deana A, Marin O, Cesaro L, Gunby RH, Ferrarese A, Coluccia AM, Tartari CJ, Mologni L, Scapozza L, Gambacorti-Passerini C, Pinna LA. Unique substrate specificity of anaplastic lymphoma kinase (ALK): development of phosphoacceptor peptides for the assay of ALK activity. Biochemistry. 2005;44:8533–8542. [PubMed]
37. Hastie CJ, McLauchlan HJ, Cohen P. Assay of protein kinases using radiolabeled ATP: a protocol. Nature protocols. 2006;1:968–971. [PubMed]
38. Yamazaki Y, Palmer L, Alexandre C, Kakugawa S, Beckett K, Gaugue I, Palmer RH, Vincent JP. Godzilla-dependent transcytosis promotes Wingless signalling in Drosophila wing imaginal discs. Nat Cell Biol. 2016;18:451–457. [PMC free article] [PubMed]
39. Siaw JT, Wan H, Pfeifer K, Rivera VM, Guan J, Palmer RH, Hallberg B. Brigatinib, an anaplastic lymphoma kinase inhibitor, abrogates activity and growth in ALK-positive neuroblastoma cells, Drosophila and mice. Oncotarget. 2016;7:29011–29022. doi: 10.18632/oncotarget.8508. [PMC free article] [PubMed] [Cross Ref]

Articles from Oncotarget are provided here courtesy of Impact Journals, LLC